☆ 4.6 Article

Ultra-High Prostate-Specific Antigen Level: A Potential Very-High-Risk Factor for Localized High-Risk Prostate Cancer

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial

Alison C. Tree et al.

Summary: The purpose of this study was to evaluate the efficacy and toxicity of intraprostatic lesion boosting using standard and hypofractionated radiation therapy over a 5-year period. The results showed that patients had stable disease and low toxicity after treatment.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Add to Collection

Review Oncology

Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer

Edina C. Wang et al.

Summary: Recent data suggest that the use of abiraterone acetate and prednisone may improve overall survival, disease-free survival, and metastasis-free survival in men with high-risk localized, node positive, and oligometastatic hormone-sensitive prostate cancer. The addition of potent androgen receptor inhibitors after radiation therapy may be considered after informed decision making.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Add to Collection

Article Oncology

Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy

Takanobu Utsumi et al.

Summary: The aim of this retrospective study was to identify clinical predictors of early biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa) treated with carbon-ion radiotherapy (CIRT) and androgen deprivation therapy (ADT). The study found that clinical stage, number of positive biopsy cores, and PCa classification were significantly associated with early recurrence. These predictors can help clinicians identify patients who are at risk of early recurrence.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard et al.

Summary: The combination therapy of abiraterone acetate with prednisolone showed significantly higher rates of metastasis-free survival compared with ADT alone in men with high-risk non-metastatic prostate cancer. This combination therapy may be considered a new standard treatment for this patient population.

LANCET (2022)

Add to Collection

Article Oncology

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

Nicholas D. James et al.

Summary: This study found that adding docetaxel did not significantly improve metastatic progression-free survival in non-metastatic prostate cancer patients receiving long-term treatment. However, it did improve failure-free survival and progression-free survival without increasing late toxicity. There was no strong evidence for overall survival benefit.

JNCI CANCER SPECTRUM (2022)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial

Linda G. W. Kerkmeijer et al.

Summary: The study found that focal boosting of the macroscopic visible tumor with external beam radiotherapy increases biochemical disease-free survival in patients with localized intermediate- and high-risk prostate cancer. There were no significant differences in prostate cancer-specific survival, overall survival, toxicity, and health-related quality of life between the focal boost arm and the standard treatment arm.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer

Scott C. Morgan et al.

Summary: The role of local therapy in metastatic prostate cancer is evolving, with recent large-scale randomized trials suggesting that radiotherapy directed at the prostate can improve overall survival in patients with low metastatic burden. A study of patients with newly-diagnosed metastatic hormone-sensitive prostate cancer revealed that receipt of prostate radiotherapy was associated with improved overall survival, with higher radiation doses also showing a positive impact on survival outcomes.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients

Hiromichi Ishiyama et al.

Summary: This study reported outcomes and risk factors of ultrahypofractionated radiotherapy for Japanese prostate cancer patients. The results showed that initial prostate-specific antigen levels and neoadjuvant androgen deprivation therapy were risk factors for biochemical recurrence, while biologically effective dose was associated with late genitourinary and gastrointestinal toxicities. The study concluded that ultrahypofractionated radiotherapy provided effective and safe treatment for Japanese prostate cancer patients, but higher prescribed doses might lead to higher toxicity rates.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial

Julia R. Murray et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Add to Collection

Article Medicine, General & Internal

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman et al.

LANCET (2020)

Add to Collection

Review Urology & Nephrology

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

Sarah Burdett et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Oncology

Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

Akram Saad et al.

RADIATION ONCOLOGY (2017)

Add to Collection

Article Oncology

Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy? A Population-based Study

Yaacov R. Lawrence et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)

Add to Collection

Article Oncology

Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium

Hiromichi Ishiyama et al.

BRACHYTHERAPY (2017)

Add to Collection

Article Oncology

Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation

Amol K. Narang et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)

Add to Collection

Article Oncology

Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: Outcome and toxicity

Yasuhiro Yamada et al.

BRACHYTHERAPY (2015)

Add to Collection

Article Urology & Nephrology

The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy

Zachary S. Zumsteg et al.

EUROPEAN UROLOGY (2015)

Add to Collection

Review Urology & Nephrology

Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature

Jurgen J. Futterer et al.

EUROPEAN UROLOGY (2015)

Add to Collection

Article Oncology

Very-high-risk localized prostate cancer: definition and outcomes

D. Sundi et al.

PROSTATE CANCER AND PROSTATIC DISEASES (2014)

Add to Collection

Review Urology & Nephrology

The utility of prostate-specific antigen in the management of advanced prostate cancer

E. David Crawford et al.

BJU INTERNATIONAL (2013)

Add to Collection

Article Biophysics

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

Y. Kanda

BONE MARROW TRANSPLANTATION (2013)

Add to Collection

Article Oncology

Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis

Alessia Guarneri et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Treatment Outcomes in Non-Metastatic Prostate Cancer Patients With Ultra-High Prostate-Specific Antigen

Patricia Tai et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)

Add to Collection

Article Oncology

IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS

George Rodrigues et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

Add to Collection

Article Oncology

EXTREME-RISK PROSTATE ADENOCARCINOMA PRESENTING WITH PROSTATE-SPECIFIC ANTIGEN (PSA) >40 NG/ML: PROGNOSTIC SIGNIFICANCE OF THE PRERADIATION PSA NADIR

Abraham S. Alexander et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

Add to Collection

Article Urology & Nephrology

Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men

T Fukagai et al.

BJU INTERNATIONAL (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.